featured
Identifying Baseline Serum and Stool Microbiome Biomarkers Predicting the Outcomes of Ritlecitinib Induction Therapy in Patients With Ulcerative Colitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Crohn's & Colitis
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis
J Crohns Colitis 2024 Sep 03;18(9)1361-1370, M Hassan-Zahraee, Z Ye, L Xi, E Dushin, J Lee, J Romatowski, J Leszczyszyn, S Danese, WJ Sandborn, C Banfield, JD Gale, E Peeva, RS Longman, CL Hyde, KE HungFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.